Bank of America heads into its May 4 Q2 earnings report having recovered sharply from April's tariff-driven selloff, with the analyst community firmly behind the rally.
The price recovery is the dominant story. BAC closed April at $53.46, up 13% on the month — one of the stronger rebounds across the major bank complex. Close peers WFC and JPM both lagged materially over the same stretch, with JPM gaining roughly 0.5% on the week versus BAC's near 2% advance. The P/E multiple has expanded by roughly half a point over 30 days to 11.4x, and the price-to-book ratio has risen about 0.1 turns to 1.28x — valuation that has re-rated upward alongside the share price, compressing the margin for error on the print.
The analyst community shifted direction decisively after the Q1 release on April 15. Several firms — including Evercore ISI, Truist, Oppenheimer, and KBW — lifted their price targets into the $59–$64 range, all while maintaining positive ratings. That follows a brief period in early April when JPMorgan and Evercore trimmed targets on macro concerns. The mean target now stands at $62.93, implying roughly 18% upside from current levels. The bull case rests on 7% year-over-year revenue growth, a 9% rise in net interest income, and 21% net income growth in consumer banking. Bears point to the CET1 ratio slipping to 11.2% and the supplementary leverage ratio falling 20 basis points to 5.5%, alongside macro risks — inflation, potential recession — that could still pressure asset quality.
Short positioning offers little drama here. At just 1.4% of the free float — down 7.6% over the past month — short sellers have been reducing exposure into the rally. The lending market is relaxed: cost to borrow runs below 0.5% despite a roughly 37% rise on the week from a very low base, and the ORTEX short score of 30.6 places BAC well into uncontested territory. Options positioning is mildly defensive — the put/call ratio is running at 1.23, slightly above its 20-day average of 1.20, but barely half a standard deviation above the mean and nowhere near the 52-week high of 1.67. Insider activity has been one-directional: the CEO Brian Moynihan, the COO, and several Co-Presidents all recorded net sales since March, with aggregate insider net value sold over 90 days running above $52 million. These appear largely award-linked given simultaneous award entries, but the pattern is worth noting.
The May 4 report will test whether the NII momentum and consumer banking strength that drove Q1 beats can be sustained against a tightening capital ratio — and whether a stock that has already re-rated 13% in a month has priced in enough of the good news.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
